The American Modern society of Clinical Oncology–School of American Pathologists (ASCO–CAP) rules have continued to evolve to improve the accuracy and clinical utility of HER2 screening by supplying unique algorithms15,16. In parallel with current techniques, novel ways to quantify HER2 stages or standardize processes are now being investigated, including quantitative https://www.directivepublications.org/journal-of-clinical-breast-cancer/